Circulating tumor DNA as prognostic markers of relapsed breast ...

In this review, ctDNA measurements at different timepoints are correlated with evaluation indexes at different periods after treatment.

The ctDNA can be used as an early potential postoperative prognosis biomarker in breast cancer, and also as a reference index to evaluate the therapeutic ...

Circulating Tumor DNA as a Predictive Marker of Recurrence for ...

Circulating tumor DNA (ctDNA) has been proven to be a marker of disease progression in metastatic breast cancer. We aimed to evaluate the prognostic value of ...

Circulating tumor DNA for predicting recurrence in patients with ...

The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous ...

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Circulating Tumor DNA and Survival in Metastatic Breast Cancer

Meaning These findings suggest the potential of ctDNA detection as a prognostic biomarker in patients with metastatic breast cancer and may help ...

Early evaluation of circulating tumor DNA as marker of therapeutic ...

We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast ...

Use of ctDNA in early breast cancer: analytical validity and clinical ...

Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, ...

Serial Postoperative Circulating Tumor DNA Assessment Has ...

The Signatera assay detected ctDNA up to 3 years before overt breast cancer relapse in the EBLIS patient population. The prognostic association ...

Circulating tumor DNA: from discovery to clinical application in ...

Several studies have examined ctDNA as a prognostic marker in breast cancer treated with immunotherapy. ... circulating tumor DNA predicts relapse ...

Circulating tumor DNA for predicting recurrence in patients with ...

The search strategy included domains related to 'breast cancer', 'circulating tumor DNA', and outcomes ('prognosis' or 'survival') and was ...

The prognostic role of circulating tumor DNA across breast cancer ...

ctDNA was more predictive of recurrence-free survival and overall survival in the HR- subgroup than in the HR+ subgroup, and the same result was showed in the ...

ctDNA and residual cancer burden are prognostic in triple-negative ...

Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for ...

Personalized Detection of Circulating Tumor DNA Antedates Breast ...

Plasma ctDNA was detected ahead of clinical or radiologic relapse in 16 of the 18 relapsed patients (sensitivity of 89%); metastatic relapse was ...

Circulating Tumor DNA and Disease-Free Survival in Breast Cancer

Similarly, Tan et al reported that circulating cell-free DNA is a strong predictive and prognostic marker in patients with breast cancer.

Circulating Tumor DNA Predicts the Response and Prognosis in ...

Many patients with breast cancer still relapse after curative treatment. How to identify the ones with high relapse risk remains a critical ...

The Role of Ki-67 and ctDNA as Prognostic or Predictive Markers in ...

Circulating tumor DNA (ctDNA) analysis is also emerging to detect minimal residual disease (MRD), especially in early-stage breast cancer after ...

Circulating tumor DNA as a prognostic marker in high-risk ...

Currently, there is no reliable blood-based marker to track tumor recurrence in endometrial cancer (EC) patients.

Circulating tumor DNA (ctDNA) as prognostic markers of relapsed ...

Request PDF | Circulating tumor DNA (ctDNA) as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis ...

Role of ctDNA in Breast Cancer - MDPI

Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made ...